AstraZeneca's CARES Phase III Clinical Programme Fails to Meet Primary Endpoint
AstraZeneca (AZN) reported that its global CARES Phase III clinical programme for anselamimab did not meet the primary endpoint in treating advanced kappa light chain amyloidosis. However, it showed a statistically significant and clinically meaningful benefit as first-line therapy added to standard treatments.
Tickers: $AZN
Topics: anselamimab astraZeneca clinical_trials pharma